Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
OBJECTIVES The current study tested the hypothesis that NM-702 improves treadmill exercise performance in peripheral arterial disease patients with claudication-limited exercise performance . BACKGROUND Patients with claudication experience significant disability , owing to their exercise limitation . Therapeutic options to improve exercise performance in these patients are limited . NM-702 is a novel drug that inhibits phosphodiesterase as well as thromboxane A2 synthase . METHODS This study was a r and omized , multi-center , placebo-controlled , double-blind trial . Patients were r and omized to receive 24 weeks of twice-daily treatment with either placebo ( intent to treat population , n = 130 ) , 4 mg NM-702 ( n = 126 ) , or 8 mg NM-702 ( n = 130 ) . RESULTS After 24 weeks of treatment , 8 mg NM-702 was associated with a statistically significant increased peak walking time on a grade d treadmill as compared with placebo ( p = 0.004 ) . Peak walking time after 24 weeks was increased by 17.1 + /- 49.0 % in the placebo arm , 22.1 + /- 60.1 % in the 4-mg NM-702 arm , and 28.1 + /- 50.5 % in the 8-mg NM-702 arm . NM-702 at the 8-mg dose for 24 weeks was associated with statistically significant improvements in the treadmill claudication onset time as compared with placebo . In addition , as compared with placebo , NM-702 improved the physical component and physical functioning scores of the Medical Outcomes Study 36-Item Short Form and the walking distance and stair climbing domains of the Walking Impairment Question naire . NM-702 was generally well tolerated , but adverse events typical of vasodilators were common . CONCLUSIONS NM-702 used for 24 weeks by patients with claudication was associated with improvements in laboratory- and ambulatory-based exercise performance
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .